Quant Rating Data for development-stage pharma companies such as Intra-Cellular Therapies tells but a partial story.
Sell Side Ratings on Seeking Alpha are broadly positive for a variety of early-stage biotechs of varying degrees of merit.
Lumateperone (ITI-007) is a pipeline in a molecule that is undergoing a rough startup which will shortly face a huge PDUFA test.
Assuming good lumateperone news, expect a daunting trek through the danger zone as Intra-Cellular works to build its newly approved schizophrenia therapy to the other side of the rainbow.
Recently, I was checking out a Seeking Alpha feature that was new to me under the "My Portfolio" tab. It is the nifty feature that sets out a multicolumn view of each stock in a